Cardiovascular Events, Conditions, and Procedures Among People With Episodic Migraine in the US Population: Results from the American Migraine Prevalence and Prevention (AMPP) Study. Issue 1 (12th November 2016)

• Record Type: Journal Article
• Authors: Buse, Dawn C.; Reed, Michael L.; Fanning, Kristina M.; Kurth, Tobias; Lipton, Richard B.
• Is Part Of: Headache. Volume 57:Issue 1(2017)
• Page Start: 31
• Page End: 44
• Publication Date: 2016-11-12
• Subjects: cardiovascular -- episodic migraine -- stroke -- triptan -- AMPP study -- myocardial infarction; Headache -- Periodicals; Headache -- Periodicals; 616.8491
• DOI: 10.1111/head.12962
• Languages: English
• ISSNs: 0017-8748

Abstract

Abstract : Background: Though migraine, particularly migraine with aura, is a cardiovascular (CV) risk factor, the scope and distribution of cardiovascular disease in representative samples of people with migraine are not known. This is important because many widely used acute migraine treatments, including triptans, ergot alkaloids, and nonsteroidal anti‐inflammatory drugs, carry precautions, warnings, or contraindications for use in persons with CV disease. Objectives: To assess the scope and distribution of cardiovascular events, conditions, and procedures in persons with episodic migraine in a representative sample of the US population, using data from the American Migraine Prevalence and Prevention (AMPP) Study. Methods: Eligible subjects completed the 2009 AMPP survey, met ICHD‐3beta criteria for migraine, and had a headache frequency of less than 15 days per month (episodic migraine). A survey on cardiovascular events (ie, myocardial infarction), conditions (ie, angina), and procedures (ie, carotid endarterectomy) was adopted from the Women's Health Study and the Physician's Health Studies. Cardiovascular events and conditions were defined by participant reports of having both experienced and received a physician diagnosis for a particular event or condition. The distribution of CV events, conditions, and procedures was summarized for the entire migraine sample and in groups defined by gender and age (22–39, 40‐59, and ≥60). To assess the numbers of persons with episodic migraine in the US, we applied age and gender stratified estimates of migraine prevalence to the 2015 Census data. To estimate the number of cardiovascular events, conditions, and procedures in the US migraine population, we applied age and gender stratified event rates to the number of persons with episodic migraine in each stratum. Results: The 2009 AMPP Study survey was returned by 11, 792 study participants out of 16, 983 (64.9% response rate), including 6723 individuals who met study criteria for episodic migraine (5227 women and 1496 men). Among 22‐39 year olds with episodic migraine, 3.4% reported having received a physician diagnosis of CV events or conditions and 1.1% reported undergoing CV related procedures. Among 40‐59 year olds, 10.2% reported having received a physician diagnosis of CV events or conditions and 3.5% reported CV related procedures. For those age 60 or older, 22.3% reported CV events or conditions and 8.8% reported CV procedures. Prevalence of events, conditions, and procedures was higher in men than women and also in older age groups. However, the absolute number of CV events, procedures, and conditions was greater for women than men due to the higher population prevalence of episodic migraine in women. We projected that 2.0 million women and 665, 000 men in the US had episodic migraine and a history of one or more CV event, condition, or procedure. By age group, it is estimated that 579, 000 among those aged 22‐39, 1.37 million of those aged 40‐59, and 696, 000 of those 60 and older with episodic migraine have ever had at least one CV event, procedure, or condition. Conclusion: Based on these analyses, we estimate that there are roughly 2.6 million people with episodic migraine aged 22 and older in the US with one or more prior CV event, condition, or procedure. For this group, cardiovascular contraindications to many migraine‐specific acute migraine therapies may make treatment challenging.